Sugi Predict

Sugi Predict / Compounds / SCHEMBL8100563

SCHEMBL8100563

SCHEMBL8100563

CC(C)(Sc1cc(C(C)(C)C)c(OC(=O)CCC(=O)O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OC(=O)CCC(=O)O)c(C(C)(C)C)c1

nearest known ligand 0.90

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ VCAM1 P19320 14/20 0.90
▸ ALOX15 P16050 4/20 0.45
▸ HPN P05981 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ SIRT5 Q9NXA8 1/20 0.45
▸ KDM6B O15054 1/20 0.35
▸ KDM5C P41229 1/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ PHF8 Q9UPP1 1/20 0.35
▸ KDM2A Q9Y2K7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13260389 0.95 VCAM1 (0.81) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL25639629 0.95 VCAM1 (0.81) VCAM1ALOX15HPNMAPTSIRT5
Succinobucol SCHEMBL347492 0.95 VCAM1 (1.00) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL8258176 0.92 VCAM1 (0.77) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL6054982 0.88 VCAM1 (0.92) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL19220490 0.88 VCAM1 (0.71) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL12103783 0.87 VCAM1 (0.69) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL8353431 0.87 VCAM1 (0.82) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL7568308 0.87 VCAM1 (1.00) VCAM1ALOX15HPNMAPTSIRT5
SCHEMBL12109918 0.86 VCAM1 (0.68) VCAM1ALOX15HPNMAPTSIRT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119424573-A Chinese and western medicine combination for treating hyperlipidemia 天津铭瑞医药科技有限公司 2025-02-14 — — CN disclosed
CN-119302932-A Pharmaceutical composition for treating hyperlipidemia 天津铭瑞医药科技有限公司 2025-01-14 — — CN disclosed
US-20170224647-A1 NEW MDR1 INHIBITORS FOR OVERCOMING MULTIDRUG RESISTANCE Universita 'Degli Studi Parma 2017-08-10 — — US disclosed
US-20100324328-A1 Process For Isolating Mono-Carboxy Substituted Probucol Derivatives ASTRAZENECA AB (SE) 2010-12-23 — — US disclosed
US-20100324328-A1 Process For Isolating Mono-Carboxy Substituted Probucol Derivatives ASTRAZENECA AB (SE) 2010-12-23 — — US disclosed
WO-2009002263-A1 PROCESS FOR ISOLATING MONO-CARBOXY SUBSTITUTED PROBUCOL DERIVATES ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
WO-2006116038-A2 PROCESS FOR THE SEPARATION OF PROBUCOL DERIVATIVES ATHEROGENICS, INC. (US) 2006-11-02 — — WO disclosed
WO-2005102323-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS, INC. (US) 2005-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224647-A1 NEW MDR1 INHIBITORS FOR OVERCOMING MULTIDRUG RESISTANCE ABCC1, ABCB1, ABCG2 VCAM1 254/4885ALOX15 2040/4885HPN 924/4885
US-20100324328-A1 Process For Isolating Mono-Carboxy Substituted Probucol Derivatives CEL, REN, F12 VCAM1 2684/4885ALOX15 2623/4885HPN 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.